1. Home
  2. LOAN vs NTRB Comparison

LOAN vs NTRB Comparison

Compare LOAN & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Manhattan Bridge Capital Inc

LOAN

Manhattan Bridge Capital Inc

HOLD

Current Price

$4.38

Market Cap

51.9M

Sector

Real Estate

ML Signal

HOLD

Logo Nutriband Inc.

NTRB

Nutriband Inc.

HOLD

Current Price

$4.15

Market Cap

57.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LOAN
NTRB
Founded
1989
2016
Country
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Industrial Specialties
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
51.9M
57.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
LOAN
NTRB
Price
$4.38
$4.15
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
24.0K
15.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
9.96%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$30.17
Revenue Next Year
$4.47
$3,394.36
P/E Ratio
$9.55
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.29
$3.96
52 Week High
$6.05
$11.68

Technical Indicators

Market Signals
Indicator
LOAN
NTRB
Relative Strength Index (RSI) 33.29 43.33
Support Level $4.48 $4.06
Resistance Level $4.58 $4.49
Average True Range (ATR) 0.07 0.25
MACD -0.00 -0.03
Stochastic Oscillator 19.32 26.47

Price Performance

Historical Comparison
LOAN
NTRB

About LOAN Manhattan Bridge Capital Inc

Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.

About NTRB Nutriband Inc.

Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.

Share on Social Networks: